10x Genomics (TXG) Projected to Post Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) will likely be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.2431) per share and revenue of $146.6740 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.19. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The company had revenue of $150.84 million for the quarter, compared to analyst estimates of $146.41 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

NASDAQ TXG opened at $46.85 on Tuesday. The stock has a market capitalization of $5.95 billion, a P/E ratio of -277.02 and a beta of 2.03. The business has a 50 day simple moving average of $37.55 and a 200 day simple moving average of $26.90. 10x Genomics has a one year low of $11.16 and a one year high of $50.34.

Analyst Ratings Changes

Several brokerages have recently commented on TXG. Barclays raised their price objective on shares of 10x Genomics from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Canaccord Genuity Group increased their target price on shares of 10x Genomics from $32.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. Morgan Stanley raised their target price on 10x Genomics from $22.00 to $37.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, Piper Sandler boosted their target price on 10x Genomics from $20.00 to $42.00 and gave the company a “neutral” rating in a research report on Wednesday, July 1st. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $32.08.

Insider Activity

In other 10x Genomics news, Director Shehnaaz Suliman sold 5,723 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $32.63, for a total value of $186,741.49. Following the completion of the transaction, the director owned 31,722 shares in the company, valued at $1,035,088.86. This represents a 15.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Taich sold 15,098 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $24.44, for a total transaction of $368,995.12. Following the sale, the chief financial officer owned 379,898 shares of the company’s stock, valued at $9,284,707.12. This trade represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 91,309 shares of company stock valued at $2,581,357 over the last ninety days. Company insiders own 8.84% of the company’s stock.

Institutional Trading of 10x Genomics

Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in 10x Genomics by 806.4% during the first quarter. Royal Bank of Canada now owns 182,836 shares of the company’s stock valued at $1,597,000 after purchasing an additional 162,665 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of 10x Genomics by 163.5% in the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company’s stock worth $5,634,000 after purchasing an additional 400,430 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of 10x Genomics in the first quarter valued at approximately $92,000. Legal & General Group Plc raised its position in shares of 10x Genomics by 5.7% in the second quarter. Legal & General Group Plc now owns 110,864 shares of the company’s stock valued at $1,284,000 after purchasing an additional 5,985 shares during the period. Finally, American Century Companies Inc. purchased a new stake in shares of 10x Genomics during the 2nd quarter valued at approximately $933,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.